7 citations
,
January 2018 in “Reproduction” Inhibiting 5α-reductase increases progesterone levels in late pregnant mares.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
1 citations
,
December 2005 in “The Journal of Urology” Combination therapy for BPH is more effective in certain men but may not be cost-effective due to minimal impact and potential side effects.
1 citations
,
October 2011 in “Hospital Pharmacy” 3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
1 citations
,
January 2013 in “MedChemComm” PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
3 citations
,
August 2020 in “Urology Journal” Using 5-alpha reductase inhibitors may increase the risk of mild depression.
8 citations
,
April 2004 in “The Journal of Urology” Doxazosin and finasteride negatively affect sexual function in men with BPH.
January 2008 in “프로그램북(구 초록집)” 5 citations
,
November 2015 in “Journal of Enzyme Inhibition and Medicinal Chemistry” Certain derivatives are more effective 5α-reductase type 2 inhibitors than finasteride.
33 citations
,
January 2016 in “Skin appendage disorders” The document concludes that sexual and psychiatric side effects from 5-alpha-reductase inhibitors are reported, but more high-quality research is needed to understand how often they occur.
12 citations
,
December 2012 in “Current Drug Targets” The Androgen Receptor could be a target for treating diseases like cancer, but more research is needed to confirm the effectiveness of potential treatments.
50 citations
,
May 2000 in “Fertility and Sterility” Flutamide reduces hair growth better but has more side effects.
30 citations
,
June 2010 in “Endocrine Related Cancer” SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.
3 citations
,
November 2018 in “The Journal of Clinical Psychiatry” Odds Ratios can be misleading; it's better to also present risk and Relative Risks for clarity.
26 citations
,
February 2020 in “International Journal of Biological Macromolecules” Chitosan-coated dutasteride nanocapsules improve hair treatment, and physical stimulation boosts effectiveness.
September 2003 in “Reactions Weekly”
1 citations
,
April 2019 in “Clinical Breast Cancer” Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.
14 citations
,
November 2014 in “European journal of medicinal chemistry” Researchers found new potential treatments for conditions related to the androgen receptor, like male hormonal contraception, by testing thousands of compounds.
April 2020 in “Archivos españoles de urología” Dutasteride does not seem to change rat spermatogenesis or oxidative stress.
7 citations
,
January 2022 in “Bioengineering” The formulation with oleic acid may be better for treating male pattern baldness.
34 citations
,
July 2011 in “International journal of pharmaceutics” Ion-paired risedronate significantly increases skin penetration without irritation compared to risedronate alone.
15 citations
,
January 2018 in “Acta dermato-venereologica” Finasteride and dutasteride increase sexual dysfunction risk by 1.57 times in male hair loss treatment.
16 citations
,
November 2018 in “The journal of pain/Journal of pain” 14,15-EET may help reduce poststroke pain by affecting certain brain proteins.
7 citations
,
March 2011 in “Expert Opinion on Drug Safety” Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
5 citations
,
May 2018 in “European journal of pharmacology” Fesoterodine is effective and safe for elderly patients with overactive bladder.
January 2007 in “日本看護学会抄録集 成人看護1” Certain amino acids in 5AR1 and 5AR2 are crucial for binding and resistance to Finasteride.
11 citations
,
January 2000 in “The Journal of Steroid Biochemistry and Molecular Biology” LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.
August 2019 in “The Journal of Urology” Treatment with 5α-reductase inhibitors is linked to a delay in prostate cancer diagnosis and may affect survival rates.
December 2024 in “Therapeutic Delivery” Topical dutasteride shows promise for hair loss but needs more research.